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BACKGROUND: The relationship between prostate cancer and height is uncertain.
METHODS: We prospectively examined the association of height with prostate cancer among 34268 men in the prostate, lung,
colorectal, and ovarian cancer trial. Anthropometry was assessed at baseline and 2144 incident prostate cancer cases were identified
upto 8.9 years of follow-up.
RESULTS: Overall, tallness was not associated with the risk of prostate cancer or with the risk of non-aggressive disease, but the risk for
aggressive prostate cancer tended to be greater in taller men (Gleason score X7 or stage XIII; P trend¼0.05; relative risk (RR) for
190cmþ vs p170cm¼1.39, 95% confidence interval (95% CI): 0.96–2.01). This association was largely limited to men below the
age of 65 years (P trend¼0.008; RR for 190cmþ vs p170cm¼1.76, 95% CI: 1.06–2.93; P for interaction¼0.009), although the
number of cases was small and risk estimates were somewhat unstable.
CONCLUSION: The results of this large prospective prostate cancer screening trial suggest that tallness is associated with increased risk
for younger onset aggressive prostate cancer.
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Tallness is a potential risk factor for prostate cancer (Macinnis and
English, 2006), possibly because of increased levels of bioavailable
insulin-like growth factors (IGFs) or androgens (Tanner, 1990), or
to genetic predisposition (Silventoinen et al, 2003). This associa-
tion is supported by several, but not all, population-based studies,
with a modest pooled effect size (relative risk (RR)¼1.09, 95%
confidence interval (95% CI)¼1.06–1.12, per 10-cm increase)
based on 56 studies up to 2008 (Zuccolo et al, 2008). Since then, a
large European cohort study (1500 cases; 129502 men) reported a
null association (RR¼1.01, 95% CI¼0.98–1.04 per 5-cm increase)
(Pischon et al, 2008). It is unclear whether the association between
height and prostate cancer differs according to tumour charac-
teristics or other risk factors. In the Prostate, Lung, Colorectal, and
Ovarian (PLCO) Cancer Screening Trial, which has a standardised
prostate cancer screening protocol, we examined the relationship
of height with total prostate cancer, non-aggressive prostate
cancer, and with aggressive prostate cancer.
MATERIALS AND METHODS
The PLCO Screening Trial is a multi-centre trial designed to
evaluate screening methods for the early detection of these cancers
(Prorok et al, 2000). Briefly, more than 75000 men, aged 55–74
years, were recruited from 10 centres between 1993 and 2001 and
randomised to receive either annual prostate screening (serum
prostate-specific antigen (PSA) testing and digital rectal examina-
tion (DRE)) or standard care. Participants completed a risk factor
questionnaire at baseline, which included current weight and
height. The study was approved by the institutional review boards
at the National Cancer Institute and the screening centres, and all
participants provided informed consent.
Of the 38349 men who were randomly assigned to the screening
arm of the trial, we excluded men who reported a history of cancer
other than non-melanoma skin cancer (n¼775); men without
an initial PSA test or DRE (n¼2470); men who received an initial
screening examination, but with whom there was no subsequent
contact (n¼721); men who did not complete the baseline
questionnaire (n¼898); and men with missing (n¼205) or
extreme values for height (n¼12; o150cm). We also excluded
men whose initial screening examination occurred after 30
September 2002, the censoring date for this analysis (n¼72).
After exclusions, the analytic cohort comprised 34268 men (some
participants were included in more than one exclusion category).
For men with suspected prostate cancer from cancer screening
or for those who reported prostate cancer on their annual follow-
up questionnaire, we requested medical records to confirm the
diagnosis and to obtain TNM stage and grade information. We
used death certificates, autopsy reports, and supporting medical/
pathological records to confirm diagnosis, stage, and grade for the
deceased participants. Only histologically confirmed cases were
included in the analysis. Prostate cancers were defined as non-
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yaggressive if classified as stage I or II (localised disease) and had a
Gleason sum of o7 (low-grade disease). Tumours were considered
aggressive if classified as stage III or IV (high-stage disease) or
assigned a Gleason sum of X7 (high grade-disease). We also
distinguished between high-grade disease (defined as a Gleason
sum of X7) and high-stage disease (defined as stage III or IV).
Person-years were calculated from the date of the baseline
prostate cancer screening to the date of the most recently
completed annual follow-up questionnaire, date of diagnosis,
death, or 30 September 2002, whichever came first. We used Cox
proportional hazards regression analysis to estimate RRs and 95%
CIs. Multivariable analyses were adjusted for confounding factors,
including age (continuous), race (White, Black, Asian/Pacific
Islander, other), PLCO study centre, family history of prostate
cancer (first degree; yes, no, missing), smoking status (never,
current, former, pipe–cigar only), education (o12 years, 12 years
of high school, post high school or college, and college graduation
or more), history of diabetes (yes, no, missing), body mass index
(BMI) (18.5–24.9, 25.0–29.9, 30.0kg/m
2 or more), and number of
screenings using PSA or DRE during the trial. Tests for linear trend
were conducted by assigning the median value for each category
and treating that term as a single continuous variable in the model.
In addition, stratified analyses were carried out on the basis of age
at baseline, history of prostate cancer, race, history of diabetes,
current BMI, and BMI at age 18 years. We formally tested for
interactions using log-likelihood ratio tests. All the analyses were
conducted using SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA). All P-values were two sided.
RESULTS
Taller men were more likely to be Caucasian or African American,
to have a positive family history of prostate cancer, to smoke, and
to consume more total energy than shorter men (Table 1). Other
characteristics, including the frequency of prostate cancer screen-
ings during the trial, did not vary appreciably by height.
During 170882 person-years of follow-up of 34268 men, 2144
men were diagnosed with prostate cancer, of whom 1202 (57%)
were classified as non-aggressive and 912 (43%) as aggressive
cases. In multivariable analysis, height was associated neither
with the risk of prostate cancer overall nor with non-aggressive
disease (Table 2). However, the risk for aggressive prostate
cancer tended to be greater in taller men, with risk increasing in
a dose-response manner (Gleason score X7 or stages XIII;
P trend¼0.05; RR¼1.39, 95% CI¼0.96–2.01; comparing 190þ
with p170cm). Positive trends with height were noted for both
high-grade (Gleason score X7 only; P trend¼0.04) and high-stage
disease (stages XIII only; P trend¼0.06).
As exploratory analyses, we have examined whether relation-
ships with height differ according to prostate cancer risk factors. A
strong positive association with aggressive disease was observed
for men younger than 65 years (P trend¼0.008; RR¼1.76, 95%
CI¼1.06–2.93; comparing 190þ with p170cm). No clear pattern
was observed for men in the older (X65 years) age group. The test
for interaction between age and height was statistically significant
(P interaction¼0.009). There was no interaction between height
and other risk factors (i.e., race, diabetes, current BMI, or BMI at
age 18 years) in relation to risk (all P interactions 40.05; data not
shown).
DISCUSSION
In this large prospective study, we found that height was associated
with increased risk of aggressive prostate cancer in individuals
below the age of 65 years. As all participants in this screening trial
were screened annually using both PSA testing and DRE for the
Table 1 Baseline characteristics of participants according to height, PLCO study
a
Height (cm)
Characteristic p170 171–174.9 175–179.9 180–184.9 185–189.9 190+
Number of participants, n (%) 3472 (10.1) 6472 (18.9) 9804 (28.6) 8773 (25.6) 4276 (12.5) 1471 (4.3)
Age, years 63.4 63.1 62.7 62.3 61.9 61.7
Race, %
White 66.3 85.0 91.9 93.3 94.0 91.7
Black 4.8 4.0 4.0 4.4 4.7 6.5
Others 28.9 11 4.1 2.3 1.3 1.8
Family history of prostate cancer, % 7.2 7.6 7.2 7.5 8.3 8.7
History of diabetes, % 9.9 10.5 8.4 9.1 8.0 10.3
Daily aspirin use, % 29.3 30.9 30.5 30.7 29.6 28.9
Smoking status, %
Never 32.2 29.5 29.1 29.0 28.3 28.2
Current 10.2 11.2 11.0 11.4 11.7 10.9
Former 50.1 51.4 52.1 51.8 51.9 52.3
Cigar or pipe only 7.5 7.9 7.9 7.8 8.2 8.6
Physical activity, h per week 1.9 2.0 2.0 2.0 2.0 2.0
Total energy, kcal per day 2184 2280 2352 2412 2503 2589
Current BMI, kgm
 2 27.4 27.5 27.6 27.6 27.6 27.5
BMI at age 20, kgm
 2 23.0 22.9 23.0 23.0 22.9 22.6
PSA (baseline), ngml
 1 2.4 1.8 1.8 1.9 2.2 1.7
DRE (baseline), % 6.7 7.6 8.1 7.4 7.3 6.1
Biopsy (before study participation), % 4.5 4.0 4.3 4.4 4.0 3.9
No. of screens per year
b 0.8 0.8 0.8 0.8 0.8 0.8
BMI¼body mass index; DRE¼digital rectal examination; PLCO¼Prostate, Lung, Colorectal, and Ovarian; PSA¼prostate-specific antigen.
aMeans or proportions.
bAverage number of prostate cancer screening examinations (PSA test and/or DRE) during the period of active screening (years: 0–5).
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differential cancer detection according to height. As all prostate
cancers were evaluated uniformly for stage and grade by biopsy,
the possibility of misclassification of cases was also minimal.
More than 30 prospective and 27 case–control studies have
examined height and overall prostate cancer risk (Macinnis and
English, 2006; Zuccolo et al, 2008), but findings are mixed; some
studies showed a positive association (Le Marchand et al, 1994;
Andersson et al, 1997; Giovannucci et al, 1997; Hebert et al, 1997;
Rodriguez et al, 2001; Engeland et al, 2003; Cox et al, 2006; Sequoia
et al, 2006; Zuccolo et al, 2008), whereas others found no relation
(Severson et al, 1988; Cerhan et al, 1997; Veierod et al, 1997; Nilsen
and Vatten, 1999; Clarke and Whittemore, 2000; Pischon et al,
2008). Stronger associations were observed for more advanced or
fatal prostate cancer among 7 (Andersson et al, 1997; Giovannucci
et al, 1997, 2004; Rodriguez et al, 2001; Cox et al, 2006; Sequoia
et al, 2006; Zuccolo et al, 2008) of the 14 (Le Marchand et al, 1994;
Andersson et al, 1997; Giovannucci et al, 1997, 2004; Nilsen and
Vatten, 1999; Habel et al, 2000; Hsing et al, 2000; Norrish et al,
2000; Rodriguez et al, 2001; Macinnis et al, 2003; Cox et al, 2006;
Sequoia et al, 2006; Pischon et al, 2008; Zuccolo et al, 2008) studies
that included analyses for advanced or fatal prostate cancers.
Consistent with our findings, a recent meta-analysis reported that
the pooled estimate for aggressive or fatal prostate cancer was
slightly higher than for all prostate cancers (RR for advanced or
fatal prostate cancer¼1.12, 95% CI¼1.05–1.19, per 10-cm
increase in height) (Macinnis and English, 2006; Zuccolo et al,
2008); however, the meta-analysis showed marked between-study
heterogeneity (I
2¼47%) (Zuccolo et al, 2008).
Our finding of a stronger association with younger onset
aggressive prostate cancer is consistent with a prospective study in
Hawaii (o72.5 years, n¼31 cases) (Le Marchand et al, 1994), but
numbers were small and risk estimates unstable. No other study
has reported on the height–prostate cancer relationship according
to age. Two studies reported somewhat stronger associations with
advanced/aggressive disease in men with a positive family history
of prostate cancer (Norrish et al, 2000; Ahn et al, 2008). The
limited numbers of aggressive cases with a first-degree family
history (n¼109), prevented our examining potential interaction
with family history. Our findings require confirmation in large
consortium-based studies.
Height is influenced by bioavailable IGFs and androgens
(Tanner, 1990). Insulin-like growth factors (Roddam et al, 2008)
and androgens (Henderson et al, 2003) have been implicated in
prostate cancer, thus providing a biologically plausible link with
height. However, the reasons for stronger associations with height
in aggressive disease among younger than older men are not clear.
Further biochemical studies investigating the underlying potential
biological mechanisms are warranted.
A limitation of our study is that height was assessed by self-report
and hence was not validated. Nevertheless, the correlations between
measured and self-reported height are typically high, ranging from
0.80 to 0.95 (Willett, 1998), although men tend to overreport their
height (Spencer et al, 2002); which could have attenuated estimates
of effect toward the null. Advantages of this study include its large
size, prospective design, and reasonably detailed anthropometry
data with a substantial range in height levels. This enabled us to
examine the risk of prostate cancer according to narrow height
categories across numerous potentially important effect modifiers.
This large prospective study suggests that tallness may be
associated with increased risk of aggressive prostate cancer, parti-
cularly in younger men; confirmation is needed in other
populations.
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